We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPLP.L Regulatory News (PLP)

  • There is currently no data for PLP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

COVID-19 Update

7 May 2020 07:00

RNS Number : 1974M
Polypipe Group PLC
07 May 2020
 

 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

 

FURTHER THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION. PLEASE SEE THE CAUTIONARY STATEMENT AT THE END OF THIS ANNOUNCEMENT.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.

 

For immediate release

 

7 May 2020

 

Polypipe Group plc

COVID-19 update

 

Polypipe Group plc ("Polypipe", the "Company" or the "Group"), a leading provider of sustainable water and climate management solutions for the built environment, today provides an update following its announcement on 25 March 2020 on the impact of the COVID-19 pandemic, and the Group's response to date.

 

Current operations

We continue to prioritise the health, safety and wellbeing of our employees, adhering to government guidelines on social distancing and hygiene in all aspects of our operations.

The Group has been operating at approximately 70% below normal demand, supplied mainly from existing stock, driven by urgent NHS and care-related activity as well as some ongoing infrastructure and commercial work, and essential Repair, Maintenance, and Improvement ("RMI").

Management actions

As previously announced, in response to COVID-19, the Company has implemented a range of measures to reduce costs and conserve cash during this period. These actions include:

· furloughing approximately 60% of our workforce and keeping this under constant review as circumstances change;

· severely curtailing capital expenditure, which was expected to have been approximately £25 million for the FY20 financial year;

· standing down all agency staff and any consultants;

· curtailing discretionary spend whilst honouring contractual payment terms with creditors;

· negotiating temporary lease terms with some providers and agreeing return to normal (non-early) payment terms with some suppliers;

· cancelling the FY19 final dividend which was due for payment on 28 May 2020, saving the Group £16 million of cash;

· reductions in base salary/fees for both executive directors and non-executive directors of 20% until further notice;

· agreeing with HMRC that PAYE and NIC payments that are due will be deferred until June 2020 and VAT payments deferred until March 2021; and

· as set out in detail below, taking a number of steps to increase the Group's banking facilities and liquidity and also securing agreement from our banking group to temporarily waive certain requirements within the Group's Revolving Credit Facility Agreement (the "RCF") as a result of the impact of COVID-19 on the business and operations of the Group and to suspend the June 2020 quarterly leverage covenant test.

 

Financing, cash management and covenant waiver

The Group entered this period of uncertainty with a strong balance sheet and good liquidity. Excluding IFRS16, net debt at 31 December 2019 stood at £150.0 million, representing 1.5 times EBITDA on a pre IFRS16 basis. Net debt as at 31 March 2020 was £184.0 million reflecting normal working capital seasonality.

We are pleased to announce that the Group has entered into an agreement with its banking group to provide an additional £50 million revolving credit facility for a period of twelve months. This facility is in addition to the existing £300 million revolving credit facility made available under the RCF, which is committed through to November 2023, leaving the Group with £350 million of total revolving credit facilities for the next twelve months. We have also secured agreement from our banking group to temporarily waive certain requirements within the Group's RCF as a result of the impact of COVID-19 on the business and operations of the Group and to suspend the June 2020 quarterly leverage covenant test.

The Group has fully established (with all necessary programme documentation signed and dated 1 May 2020) a £100 million Euro-commercial paper programme ("ECP Programme"), initially without any public rating from a third party ratings agency, in response to the United Kingdom government's initiatives designed to help United Kingdom businesses with regard to the COVID-19 pandemic, details of which were published jointly by H.M. Treasury and the Bank of England on 23 March 2020.

Scenario analysis

Uncertainty around the scale, duration and impact of the COVID-19 pandemic on the markets in which Polypipe operates, namely the new house building and RMI market and the UK commercial and infrastructure markets, mean it is difficult at this time, to determine the impact on the performance of the Company and its subsidiaries (the "Group"), and the consequences for the Company's financial performance for the current financial year and beyond.

 

The Group has analysed a broad range of potential scenarios, primarily based on assumptions regarding the period of lockdown and the level of activity subsequently in both the Group's Residential and Commercial and Infrastructure divisions. However, this scenario analysis does not constitute financial guidance and no assurance can be given that any particular assumptions will prove correct or modelled scenarios will result.

 

This scenario analysis has focused on two key scenarios, which are summarised as follows:

- an operating case where (i) trading in April to June 2020 continues to operate at approximately 70% below FY19 levels; (ii) a phased recovery in trading in July to September 2020; and (iii) trading through September to December 2020 and throughout FY21 in the Residential division and Commercial & Infrastructure divisions at levels of 15% and 10% respectively, below that achieved in FY19 (the "Operating Scenario"); and

- a more prudent scenario where (i) trading in April to June 2020 continues to operate at approximately 70% below FY19 levels; (ii) a phased recovery in trading in July to September 2020; and (iii) trading through September to December 2020 and throughout FY21 in the Residential division and Commercial & Infrastructure divisions at levels of 25% and 20% respectively, below that achieved in FY19 (the "Prudent Scenario").

 

Although the Group entered this period of uncertainty with a strong balance sheet and good liquidity, the Group has needed to secure agreement from its banking group to temporarily waive certain requirements within the Group's RCF as a result of the impact of COVID-19 on the business and operations of the Group and to suspend the June 2020 quarterly leverage covenant test.

 

Polypipe has a strong track record of investment in new product development to drive growth and margin expansion. In recent years, Polypipe has invested between £20 million to £25 million per annum in innovative and exciting product and system launches. This investment is key to enhancing Polypipe's position as a leading provider of sustainable water and climate management solutions for the built environment and developing its 'one stop shop' offering for customers in the UK.

Rather than having to significantly curtail investment in new product development and capital expenditure and implement further cost reduction measures, all of which may damage the Company's long term operational capacity and competitive position, the Board has concluded that it is prudent to now raise equity.

Proposed equity placing

As a result, the Company has separately announced its intention to conduct a non-pre-emptive placing of new ordinary shares of the Company to raise total gross proceeds of approximately £120 million. The Chairman, Chief Executive Officer, Chief Financial Officer and some Non-Executive Directors intend to participate in the Placing.

The net proceeds from the Placing will be used to strengthen Polypipe's balance sheet and reduce overall debt. In the Prudent Scenario leverage will be reduced to 2.5x EBITDA (LTM) at the peak point in financial year 2021 creating an appropriate balance sheet structure while ensuring that the Group does not breach covenants in the financial years 2020 and 2021 or require further waivers that may or may not be forthcoming. In addition, the Placing, if completed would:

· prevent investment being constrained and business decisions influenced by a focus on leverage and covenant management for the next 12 to 24 months and therefore managing the business in a manner that may cause detriment to Polypipe's long-term prospects;

· enhance operating strength and enable continuation of organic investment in exciting new products & systems; and

· provide stability and strength to increase competitive positioning and accelerate growth post COVID-19.

If the Placing were not to proceed, in the Prudent Scenario, peak net debt would be over 6x EBITDA (LTM) compared to a covenant of 3.0x EBITDA (LTM), and the Company would breach each of its quarterly covenants out to June 2021.

Board remuneration

As set out above, the Board has agreed to reduce base salaries for Executive Directors and base fees for Non-Executive Directors by 20% from 1 April 2020 until further notice. Furthermore, the grant of awards under the Polypipe Group plc Long Term Incentive Plan have been deferred and will be reconsidered by the Remuneration Committee in due course.

 

Enquiries:

 

Polypipe

Martin Payne, Chief Executive Officer

Paul James, Chief Financial Officer

 

+44 (0) 1709 770 000

Brunswick

Nina Coad / Charles Pretzlik

 

+44 (0) 20 7404 5959

   

 

Notes to Editors:

Polypipe Group plc ("Polypipe", the "Company" or the "Group"), a leading provider of sustainable water and climate management solutions for the built environment is the largest manufacturer in the UK, and among the ten largest manufacturers in Europe, of plastic piping systems for the residential, commercial, civils and infrastructure sectors by revenue. It is also a leading designer and manufacturer of energy efficient ventilation systems in the UK.

The Group operates from 19 facilities in total, and with over 20,000 product lines, manufactures the UK's widest range of plastic piping systems for heating, plumbing, drainage and ventilation. The Group primarily targets the UK and European building and construction markets with a presence in Italy, the Netherlands, Ireland and the Middle East and sales to specific niches in the rest of the world.

 

Cautionary Statement

This Trading Update (the "Report") has been prepared in accordance with the Disclosure Guidance and Transparency Rules of the UK Financial Conduct Authority and is not audited. No representation or warranty, express or implied, is or will be made in relation to the accuracy, fairness or completeness of the information or opinions contained in this Report. Statements in this Report reflect the knowledge and information available at the time of its preparation. Certain statements included or incorporated by reference within this Report may constitute "forward-looking statements" in respect of the Group's operations, performance, prospects and/or financial condition. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions and actual results or events may differ materially from those expressed or implied by those statements. Accordingly, no assurance can be given that any particular expectation will be met and reliance shall not be placed on any forward-looking statement. Additionally, forward-looking statements regarding past trends or activities shall not be taken as a representation that such trends or activities will continue in the future. The information contained in this Report is subject to change without notice and no responsibility or obligation is accepted to update or revise any forward-looking statement resulting from new information, future events or otherwise. Nothing in this Report shall be construed as a profit forecast. This Report does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase or subscribe for any shares in the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment or investment decisions relating thereto, nor does it constitute a recommendation regarding the shares of the Company or any invitation or inducement to engage in investment activity under section 21 of the Financial Services and Markets Act 2000. Past performance cannot be relied upon as a guide to future performance. Liability arising from anything in this Report shall be governed by English Law, and neither the Company nor any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this Report or its contents or otherwise arising in connection with this Report. Nothing in this Report shall exclude any liability under applicable laws that cannot be excluded in accordance with such laws.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDUNVARRUUVRUR
Date   Source Headline
6th Apr 20213:30 pmRNSChange of Name
16th Mar 20217:00 amRNSFinal Results
11th Mar 20213:17 pmRNSHolding(s) in Company
5th Mar 20214:17 pmRNSHolding(s) in Company
3rd Mar 20219:24 amRNSHolding(s) in Company
26th Feb 20215:21 pmRNSHolding(s) in Company
26th Feb 20214:58 pmRNSTotal Voting Rights
17th Feb 20218:05 amRNSHolding(s) in Company
15th Feb 20214:22 pmRNSDirector/PDMR Shareholding
15th Feb 20211:59 pmRNSHolding(s) in Company
11th Feb 20217:00 amRNSResults of placing
10th Feb 20214:52 pmRNSProposed placing of new ordinary shares
10th Feb 20214:50 pmRNSAcquisition of ADEY
2nd Feb 20217:00 amRNSAcquisition of Nu-Heat and Trading Update
1st Feb 20213:57 pmRNSHolding(s) in Company
29th Jan 20215:32 pmRNSHolding(s) in Company
8th Jan 20218:50 amRNSHolding(s) in Company
14th Dec 20207:00 amRNSTrading Update
24th Nov 20208:25 amRNSHolding(s) in Company
17th Nov 20207:00 amRNSTrading Update
2nd Nov 20202:31 pmRNSDirector/PDMR Shareholding
2nd Nov 202010:05 amRNSBlock listing Interim Review
30th Oct 20204:26 pmRNSTotal Voting Rights
29th Oct 20202:32 pmRNSDirector/PDMR Shareholding
19th Oct 202010:09 amRNSHolding(s) in Company
7th Oct 202012:28 pmRNSHolding(s) in Company
6th Oct 202010:19 amRNSHolding(s) in Company
23rd Sep 202010:43 amRNSDirector Declaration
22nd Sep 20203:59 pmRNSDirector/PDMR Shareholding
17th Sep 20204:21 pmRNSDirector/PDMR Shareholding
15th Sep 20207:00 amRNSHalf-year Report
17th Jul 20204:26 pmRNSNon-Executive Director update
16th Jul 20209:37 amRNSHolding(s) in Company
7th Jul 20207:00 amRNSCOVID-19 Update
30th Jun 20202:41 pmRNSTotal Voting Rights
29th Jun 202012:59 pmRNSDirector Declaration
26th Jun 20204:19 pmRNSDirector/PDMR Shareholding
23rd Jun 20202:57 pmRNSDirector/PDMR Shareholding
23rd Jun 20208:28 amRNSHolding(s) in Company
22nd Jun 20204:14 pmRNSDirector/PDMR Shareholding
22nd Jun 20204:08 pmRNSDirector/PDMR Shareholding
22nd Jun 20203:06 pmRNSNon-Executive Director changes
18th Jun 20204:14 pmRNSDirector/PDMR Shareholding
17th Jun 20208:18 amRNSHolding(s) in Company
3rd Jun 202011:17 amRNSHolding(s) in Company
1st Jun 20201:24 pmRNSTotal Voting Rights
21st May 20203:05 pmRNSResult of AGM
15th May 202012:55 pmRNSHolding(s) in Company
13th May 202010:14 amRNSDirector/PDMR Shareholding
12th May 20204:01 pmRNSAnnual General Meeting 2020 - Change of Venue

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.